Skip to main content
Fig. 1 | Molecular Neurodegeneration

Fig. 1

From: Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation

Fig. 1

Expression of TLR2 in the neocortex of synucleinopathy patients and an animal model. a–c Representative images from double-immunolabeling for TLR2 with cellular markers in the neocortex of normal and PD/DLB patients. The percentages of TLR2-positive neurons (NeuN) (a), astrocytes (GFAP) (b), and microglia (Iba1) (c) in the neocortex (n = 8 per group). d–f Representative images from double-immunolabeling for TLR2 with cellular markers in the neocortex of non-tg and α-Syn-tg (Line 61) mice (9–10 month olds). The percentages of TLR2-positive neuron (NeuN) (d), astrocyte (GFAP) (e), and microglia (Iba1) (f) in the neocortex (n = 6 per group). Data are mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001; unpaired t test. Scale bar, 20 μm

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326